# DESCRIPTION

## STATEMENT OF GOVERNMENT INTEREST

- acknowledge government support

## BACKGROUND

- introduce metastasis
- motivate chloride channels
- describe GABA functions
- discuss GABAA receptor
- introduce ADAR enzyme
- describe A-to-I RNA editing
- discuss GABRA3 expression
- motivate therapeutic targets

## SUMMARY OF THE INVENTION

- provide diagnostic composition
- describe method of detecting breast cancer
- describe method of detecting breast cancer risk
- describe method of treating breast cancer
- describe method of treating breast cancer
- describe method of reducing migration
- describe use of composition for manufacture

## DETAILED DESCRIPTION OF THE INVENTION

- demonstrate correlation of GABRA3 with breast cancer survival

### I. GENERAL

- define technical and scientific terms
- provide definitions for clarity
- define "a" or "an"
- define "about"
- define "patient" or "subject"
- define "control" or "control subject"
- define "predetermined control"
- define "any intervening amount"
- define "sample"
- define "microarray"
- define "ligand"
- define "polynucleotide"
- define "oligonucleotide"
- define "antibody" or "antibodies"
- describe antibody fragments
- describe altered or mutated antibodies
- define "reagent" or "ligand"
- define "labels" or "reporter molecules"
- describe GABA and GABRA3
- describe GABRA3 subunit

### II. DIAGNOSTIC COMPOSITIONS

- describe diagnostic compositions for breast cancer detection
- describe ligands for GABRA3 detection
- describe polynucleotide or oligonucleotide ligands
- describe protein or peptide ligands
- describe antibody or fragment ligands
- describe recombinant molecules bearing binding portions
- describe labeled antibodies
- describe enzyme systems for signal detection
- describe colored latex microparticles
- describe fluorescent compounds
- describe radioactive compounds or elements
- describe primer sets or primer-probe sets
- describe reagent-GABRA3 complex detection
- describe labels or substrates for reagents
- describe immobilization of reagents
- describe substrates for immobilization
- describe diagnostic kits

### II. DIAGNOSTIC METHODS

- provide diagnostic methods for breast cancer
- detect GABRA3 in sample
- indicate breast cancer with GABRA3 presence
- indicate breast cancer with increased GABRA3 level
- use control from normal breast tissue or cells
- detect risk of breast cancer metastasis
- measure GABRA3 level in biological sample
- indicate increased risk of metastasis with increased GABRA3 level
- use control from normal breast tissue or cells
- detect risk of breast cancer metastasis with A-to-I RNA edited GABRA3
- measure A-to-I RNA edited GABRA3 level in biological sample
- indicate increased risk of metastasis with decreased A-to-I RNA edited GABRA3 level
- describe ADAR editing of RNA
- detect GABRA3 using various assay formats
- describe protein assays for GABRA3 detection
- describe nucleic acid assays for GABRA3 detection
- provide examples of primers for GABRA3 detection
- describe use of diagnostic reagents and instruments for GABRA3 detection

### II. TREATMENT METHODS

- provide methods of treating breast cancer
- inhibit action of GABA in subject
- treat subject with GABAA receptor antagonist
- reduce level of expression or activity of GABRA3
- detect presence or measure level of GABRA3 in biological sample
- treat subject with reagent that inhibits action of GABA
- describe GABAA receptor antagonists
- list examples of GABAA receptor antagonists
- describe dosages and treatment regimens
- administer GABAA receptor antagonist prior to or during chemotherapy or radiation
- administer GABAA receptor antagonist prior to or during surgery
- administer GABAA receptor antagonist after surgery
- administer GABAA receptor antagonist prior to or during second or repeated course of chemotherapy or radiation
- describe dosage required for GABAA receptor antagonists
- determine effective dosage of each active component
- describe effective amount of GABAA receptor antagonist
- administer GABAA receptor antagonist in combination with other pharmaceutical agents
- describe therapeutic compositions administered by methods
- administer therapeutic compositions directly into environment of targeted cell
- describe routes of administration
- prepare therapeutic compositions for administration
- describe carrier for therapeutic compositions
- provide alternate compositions that do not meet characteristics required to cross blood-brain-barrier
- screen molecules for use in cancer therapy
- contact mammalian cancer or tumor cell culture with potential therapeutic molecule
- culture cell and test for inhibition of cellular migration
- inhibit, suppress or down-regulate expression or overexpression of GABRA3
- administer therapeutically effective dose of reagent that binds to or interacts with GABRA3
- use antibody or antibody fragment specific for GABRA3
- use small molecule that binds to three dimensional structure of GABRA3
- use nucleic acid sequences or molecules that bind, hybridize to, or amplify target sequence
- describe antisense nucleotide sequence or small nucleic acid molecule
- use short interfering nucleic acid molecule
- describe siRNA or shRNA molecule
- design si/shRNA to avoid seed matches in 3'UTR of cellular genes
- increase level of A-to-I RNA edited GABRA3
- provide A-to-I edited mRNA or coding sequence to subject
- use viral vectors to provide A-to-I edited mRNA or coding sequence
- use composition comprising reagent that decreases GABRA3 levels of expression or activity for manufacture of medicament

### II. EXAMPLES

- introduce examples of the invention
- describe metastasis in breast cancer
- perform bioinformatics analysis using TCGA breast cancer data
- identify 41 genes associated with breast cancer survival
- describe GABRA3 gene expression in breast cancer cells
- introduce Example 1: Materials and Methods
- describe TCGA data analysis
- perform Cox regression analysis
- identify genes associated with breast cancer survival
- describe lentivirus transfection and transduction
- generate MCF7 cells stably overexpressing GABRA3
- describe mammary fat pad injections
- perform orthotopic injections
- describe Transwell migration and invasion assay
- perform cell migration assays
- describe RNA isolation, reverse transcription, and real-time PCR analysis
- perform real-time PCR
- describe Western blotting
- perform Western blot analysis
- describe flow cytometry
- perform surface FACS analysis
- describe RNA isolation and GABRA3 RNA editing analysis
- perform nested PCR
- introduce Example 2: Identification of GABRA3 in Breast Cancer Progression
- analyze RNA-seq of TCGA breast cancer and normal breast tissue data
- identify genes critical for breast cancer progression
- describe GABRA3 expression pattern in normal human tissues
- perform immunoblotting of GABRA3 in human breast cancer cell lines
- analyze GABRA3 expression in paired human breast cancer samples
- introduce Example 3: GABRA3 Promotes Breast Cancer Invasion and Metastasis In Vitro and in Mouse Models
- assess GABRA3 contribution to cell migration and invasion
- perform migration and invasion assays
- measure metastasis-promoting activity of GABRA3 in vivo
- introduce Example 4: RNA-Edited GABRA3 Suppresses Breast Cancer Invasion and Metastasis In Vitro and in Mouse Models
- explore RNA editing of GABRA3 in human breast cancer cells
- determine ADAR1 and ADAR2 expression in breast cancer cell lines
- introduce RNA-edited GABRA3 into MDA-MB-436 cells
- perform migration and invasion assays
- measure metastasis-suppressing activity of RNA-edited GABRA3 in vivo
- introduce Example 5: RNA-Edited GABRA3 Reduces GABRA3 Protein Expression on the Cell Surface and Suppresses AKT Activation
- determine GABRA3 expression on cell surface using FACS analysis
- determine AKT activation in breast cancer cells
- introduce Example 6: Treatment of Breast Cancer Cells with GABRA3 Inhibitors
- treat breast cancer cells with GABRA3 inhibitors

